New diabetes drug aims to improve blood sugar control for patients on two medications
NCT ID NCT07379333
First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study tests a new medicine called HM11260C in adults with type 2 diabetes whose blood sugar is still too high despite taking metformin and dapagliflozin. About 118 people will receive either the new drug or a placebo for 36 weeks. The main goal is to see if the drug lowers HbA1c, a key measure of blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea Bucheon St. Mary's Hospital
RECRUITINGGyeonggi-do, South Korea
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.